18F-FDG PET/CT Imaging Detects Therapy Efficacy of Anti-EMMPRIN Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts

Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors

(2010) F. E. Escorcia et al.   CANCER RESEARCH

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

(2010) Devin Schellenberg et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Performance Evaluation of the FLEX Triumph X-PET Scanner Using the National Electrical Manufacturers Association NU-4 Standards

(2010) R. Prasad et al.   JOURNAL OF NUCLEAR MEDICINE

Advanced pancreatic carcinoma: current treatment and future challenges

(2010) Anastasios Stathis et al.   Nature Reviews Clinical Oncology

EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2 -mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2

(2009) F. Bougatef et al.   BLOOD

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer

(2009) N. R. Dean et al.   CLINICAL CANCER RESEARCH

Modalities for Evaluating Chemotherapeutic Efficacy and Survival Time in Patients with Advanced Pancreatic Cancer: Comparison between FDG-PET, CT, and Serum Tumor Markers

(2009) Masaki Kuwatani et al.   INTERNAL MEDICINE

Early Therapy Evaluation of Combined Anti-Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging

(2008) H. Kim et al.   CANCER RESEARCH